Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.62%
#4 aPriori aPriori +181.23%
#5 Bedrock Bedrock +79.53%
#6 Cysic Cysic +51.82%
#7 Prom Prom +46.77%
#8 Playnance Playnance +34.89%
#9 Bitway Bitway +29.28%
#10 COTI COTI +25.62%
Coin of the day
Wrapped One Wrapped One
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
American Oriental Bioengineering, Inc. American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc.

AOBI
Kedudukan dalam Saham #42790
American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China,... American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China, focuses its operations on the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical and healthcare products. The company's core pharmaceutical offerings include a range of prescription medications. Among these are the Shuanghuanglian Lyophilized Injection Powder (SHL brand), prescribed to treat flu symptoms such as elevated fever, coughs, and sore throats, as well as to address upper respiratory tract infections, mild pneumonia, bronchitis, and tonsillitis. Another significant prescription product is the Cease Enuresis Soft Gel (CE Gel brand), formulated to alleviate bedwetting. AOBI's portfolio also extends to various over-the-counter (OTC) pharmaceutical solutions. These feature the Cease Enuresis Patch for managing bedwetting and urinary incontinence; Jinji Capsule, used for conditions like endometritis, annexitis, and pelvic inflammations; Jinji Yimucao, designed to relieve premenstrual syndrome (PMS) and other related menstrual and menopausal discomforts; and Boke Nasal Spray, which offers relief for sinus congestion associated with the common cold, nasal stuffiness, chronic rhinitis, allergic rhinitis, and nasosinusitis. Furthermore, the company develops and markets a selection of nutraceutical products, notably including soybean peptide-based items available as beverages, tablets, powders, and instant coffee. Beyond its manufacturing activities, AOBI is also involved in the wholesale and retail distribution of both its pharmaceutical and nutraceutical goods. The company's products are sold across the People's Republic of China through both direct channels and a network of distributors, reaching hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical retailers, and various other retail outlets.
Harga Saham
$0.0012
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$88.00
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
140.00%
Negara
CN
Perdagangan American Oriental Bioengineering, Inc. (AOBI)

Kategori

Healthcare
Nisbah P/E bagi American Oriental Bioengineering, Inc. (AOBI)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini American Oriental Bioengineering, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi American Oriental Bioengineering, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.